Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,490 across all filing types
Latest filing 2025-08-01 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Share Issue/Capital Change Classification · 85% confidence The document is a detailed monthly return to the Hong Kong Stock Exchange covering movements in authorized/registered share capital, issued shares, share options exercised, and other capital changes under Chapter 19B of the Listing Rules. It is not an investor presentation, earnings release, or full financial report, but specifically an announcement of share issues and capital structure changes. Therefore, it fits the Share Issue/Capital Change category.
2025-08-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025
Share Issue/Capital Change Classification · 75% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer … on Movements in Securities,” detailing authorized/registered share capital and issued share movements for the month ended 31 July 2025. This is a recurring regulatory filing focused specifically on capital structure changes (authorised share capital, issued shares, treasury shares). It does not present financial performance or management commentary, nor is it an announcement of a report publication. It is best classified under the Share Issue/Capital Change category (SHA).
2025-08-01 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 92% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing multiple exercises of share options and subsequent issuance of new shares. It is not a full annual or interim report, nor an earnings release or management update. It specifically reports changes in issued and treasury shares pursuant to listing rules, with the company issuing new equity shares on specified dates. This falls under “Share Issue/Capital Change” rather than a general regulatory filing or repurchase notice.
2025-07-29 English
(1) THE LICENSE AGREEMENT FOR PD-1/VEGF BISPECIFIC ANTIBODY (SSGJ-707) WITH PFIZER COMING INTO EFFECT&#x3b; AND (2) PROPOSED SUBSCRIPTION OF NEW SHARES BY PFIZER UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 95% confidence The document is a Hong Kong stock exchange announcement detailing a License Agreement coming into effect and, more importantly, the proposed subscription of new shares by Pfizer under the company’s existing General Mandate. It outlines the number of shares, subscription price, conditions precedent, general mandate details, and use of proceeds. This fits the definition of a share issue/capital change announcement rather than an earnings release, AGM material, or full financial report. Therefore, it should be classified as a Share Issue/Capital Change (Code: SHA).
2025-07-24 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025
Regulatory Filings Classification · 90% confidence The document is a mandatory monthly return filed with the Hong Kong Stock Exchange (Form FF301) under Chapter 19B of the Listing Rules. It details movements in authorized and issued share capital for the month, with zero changes. This is a routine regulatory submission rather than an earnings release, director dealing, dividend notice, or capital raise announcement. It does not fall into any more specific category (e.g., share issue or capital change, since no changes occurred), so the appropriate classification is Regulatory Filings (RNS).
2025-07-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings Classification · 90% confidence The document is a mandatory monthly return filed to the Hong Kong Exchange under Chapter 19B of the Listing Rules outlining movements in share capital, issued shares, share options, and related confirmations. It is neither an earnings release nor a formal annual or interim report, nor a capital-raising announcement in itself, but a routine regulatory submission. There is no indication this is an AGM material, proxy, dividend notice, or specific share issuance event beyond the routine exercise of options. Therefore, it falls under the general “Regulatory Filings” fallback category.
2025-07-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.